Altamira Therapeutics Ltd.
CYTOF
$0.10
$0.0223.63%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 64.63% | 64.63% | -- | -- | 27.00% |
| Total Depreciation and Amortization | 27.63% | 27.63% | -- | -- | -7.03% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -223.09% | -223.09% | -- | -- | -41.23% |
| Change in Net Operating Assets | 99.17% | 99.17% | -- | -- | 111.89% |
| Cash from Operations | 56.80% | 56.80% | -- | -- | 62.00% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -166.67% | -166.67% | -- | -- | 200.00% |
| Cash from Investing | -166.67% | -166.67% | -- | -- | 200.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 13.42% | 13.42% | -- | -- | 57.61% |
| Issuance of Common Stock | -- | -- | -- | -- | -56.12% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 86.88% | 86.88% | -- | -- | 68.98% |
| Cash from Financing | -85.37% | -85.37% | -- | -- | -70.11% |
| Foreign Exchange rate Adjustments | -64.36% | -64.36% | -- | -- | -64.31% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -51.06% | -51.06% | -- | -- | -1,822.16% |